Global Erythropoiesis Stimulating Agents Market
Global Erythropoiesis Stimulating Agents Market

Erythropoiesis Stimulating Agents Comprehensive Study by Type (Epoetin Alfa, Epoetin Beta, Epoetin Omega, Epoetin Delta, Darbepoetin Alfa), Application (Cancer, Renal Disorders, Anti-retroviral Treatment, Neural Diseases, Other), Dosage (2000-4000 IU, 6000-10000 IU, Above 10000 IU), Drug Class (Biologics, Biosimilars) Players and Region - Global Market Outlook to 2025

Erythropoiesis Stimulating Agents Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 236 Pages 215 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Erythropoiesis Stimulating Agents Market?

Erythropoiesis Stimulating Agents (ESAs) are used to increase the differentiation of progenitor cells to red blood cells in the treatment of anemia in chronic kidney disease to reduce transfusion requirements and anemia symptoms. The deficiency of iron is one of the major causes of anemia and insufficient red blood cells production. According to a secondary source, in United States, ~661,000 people are affected by kidney failures and 1.2 million people have HIV and this number is anticipated to increase in upcoming years. This will increase the demand for erythropoiesis stimulating agents in the country. To curb the rising incidence of anemia, demand for erythropoiesis stimulating agents is expected to increase over the coming years

The market study is being classified by Type (Epoetin Alfa, Epoetin Beta, Epoetin Omega, Epoetin Delta and Darbepoetin Alfa), by Application (Cancer, Renal Disorders, Anti-retroviral Treatment, Neural Diseases and Other) and major geographies with country level break-up.

Amgen Inc. (United States), Thermo Fisher Scientific (United States), Johnson and Johnson (United States), F. Hoffmann La Roche (Switzerland), Pfizer, Inc (United States), Celltrion, Inc (South Korea), BioSidus (Argentina), Intas Pharmaceuticals Ltd (India), Teva Pharmaceutical Industries Ltd (Israel), Ranbaxy Laboratories Ltd (India), LG Life Sciences Ltd. (South Korea), VHB Life Sciences Ltd. (India), Dr. Reddy’s Laboratories Ltd (India), Beijing Four Rings Bio-Pharmaceutical Co.,Ltd. (China) and Kyowa Kirin Co., Ltd. (Japan) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Zuventus Health Care (India), Serum Institute of India (India), Biocon Limited (India) and Shandong Kexing Bioproducts Co. Ltd (China).

The competitive nature of the key manufacturers involved in the global Erythropoiesis stimulating agents market has led to increasing their focus on continuous product development and partnership alliances to strengthen their market presence globally. Also, a growing number of third-party distributors and dealers will help in expanding the product reach and drive the manufacturer's revenue in the forecast period. Research Analyst at AMA predicts that United States and European Players will contribute to the maximum growth of Global Erythropoiesis Stimulating Agents market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Erythropoiesis Stimulating Agents market by Type, Application and Region.

On the basis of geography, the market of Erythropoiesis Stimulating Agents has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2019. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Occurrence of Chronic Kidney Disease (CKD)
  • Rise in the End-stage Renal Disorder
  • Growing Demand for Darbepoetin Alfa
  • R&D Initiatives to Develop Cost-effective Solutions

Market Trend
  • Use Of Erythropoiesis Stimulating Agents In Treating Parkinson’s Disease

Restraints
  • Stringent Regulatory Guidelines

Opportunities
  • Growing Use of in Erythropoiesis in Treating HIV Infections
  • Risks of Thrombosis During Surgery and Pure Red Cell Aplasia
  • High Consumption of Erythropoietin Stimulating Agents in Emerging Economies

Challenges
  • Risk of Side Effects


In October 2019, the companies named JCR Pharmaceuticals, Chong Kun Dang Holdings, and Dong-A ST Co., Ltd. received approval for sale of their darbepoetin alfa biosimilars products in the Japanese market. Darbepoetin alfa stimulates the production of red blood cells (erythropoiesis). The majority of patients in Japan are undergoing chronic dialysis is expected to have erythropoiesis-stimulating agents for the treatment.
U.S. Food and Drug Administration issued an advisory on the safety of erythropoiesis-stimulating agents darbepoetin alfa and epoetin alfa. The new safety information contains revised product labeling that includes updated warnings, a new boxed warning, and changes to dosing instructions. The boxed warning advises physicians to monitor hemoglobin levels and adjust the dose of erythropoiesis-stimulating agents to maintain hemoglobin levels needed to avoid blood transfusion.

Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Erythropoiesis Stimulating Agents Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End Use Industry

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Epoetin Alfa
  • Epoetin Beta
  • Epoetin Omega
  • Epoetin Delta
  • Darbepoetin Alfa
By Application
  • Cancer
  • Renal Disorders
  • Anti-retroviral Treatment
  • Neural Diseases
  • Other
By Dosage
  • 2000-4000 IU
  • 6000-10000 IU
  • Above 10000 IU

By Drug Class
  • Biologics
  • Biosimilars

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Occurrence of Chronic Kidney Disease (CKD)
      • 3.2.2. Rise in the End-stage Renal Disorder
      • 3.2.3. Growing Demand for Darbepoetin Alfa
      • 3.2.4. R&D Initiatives to Develop Cost-effective Solutions
    • 3.3. Market Challenges
      • 3.3.1. Risk of Side Effects
    • 3.4. Market Trends
      • 3.4.1. Use Of Erythropoiesis Stimulating Agents In Treating Parkinson’s Disease
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Erythropoiesis Stimulating Agents, by Type, Application, Dosage, Drug Class and Region (value, volume and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Erythropoiesis Stimulating Agents (Value)
      • 5.2.1. Global Erythropoiesis Stimulating Agents by: Type (Value)
        • 5.2.1.1. Epoetin Alfa
        • 5.2.1.2. Epoetin Beta
        • 5.2.1.3. Epoetin Omega
        • 5.2.1.4. Epoetin Delta
        • 5.2.1.5. Darbepoetin Alfa
      • 5.2.2. Global Erythropoiesis Stimulating Agents by: Application (Value)
        • 5.2.2.1. Cancer
        • 5.2.2.2. Renal Disorders
        • 5.2.2.3. Anti-retroviral Treatment
        • 5.2.2.4. Neural Diseases
        • 5.2.2.5. Other
      • 5.2.3. Global Erythropoiesis Stimulating Agents by: Dosage (Value)
        • 5.2.3.1. 2000-4000 IU
        • 5.2.3.2. 6000-10000 IU
        • 5.2.3.3. Above 10000 IU
      • 5.2.4. Global Erythropoiesis Stimulating Agents by: Drug Class (Value)
        • 5.2.4.1. Biologics
        • 5.2.4.2. Biosimilars
      • 5.2.5. Global Erythropoiesis Stimulating Agents Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Erythropoiesis Stimulating Agents (Volume)
      • 5.3.1. Global Erythropoiesis Stimulating Agents by: Type (Volume)
        • 5.3.1.1. Epoetin Alfa
        • 5.3.1.2. Epoetin Beta
        • 5.3.1.3. Epoetin Omega
        • 5.3.1.4. Epoetin Delta
        • 5.3.1.5. Darbepoetin Alfa
      • 5.3.2. Global Erythropoiesis Stimulating Agents by: Application (Volume)
        • 5.3.2.1. Cancer
        • 5.3.2.2. Renal Disorders
        • 5.3.2.3. Anti-retroviral Treatment
        • 5.3.2.4. Neural Diseases
        • 5.3.2.5. Other
      • 5.3.3. Global Erythropoiesis Stimulating Agents by: Dosage (Volume)
        • 5.3.3.1. 2000-4000 IU
        • 5.3.3.2. 6000-10000 IU
        • 5.3.3.3. Above 10000 IU
      • 5.3.4. Global Erythropoiesis Stimulating Agents by: Drug Class (Volume)
        • 5.3.4.1. Biologics
        • 5.3.4.2. Biosimilars
      • 5.3.5. Global Erythropoiesis Stimulating Agents Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Erythropoiesis Stimulating Agents (Price)
      • 5.4.1. Global Erythropoiesis Stimulating Agents by: Type (Price)
  • 6. Erythropoiesis Stimulating Agents: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amgen Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Thermo Fisher Scientific (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson and Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann La Roche (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer, Inc (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Celltrion, Inc (South Korea)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. BioSidus (Argentina)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Intas Pharmaceuticals Ltd (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teva Pharmaceutical Industries Ltd (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Ranbaxy Laboratories Ltd (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. LG Life Sciences Ltd. (South Korea)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. VHB Life Sciences Ltd. (India)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Dr. Reddy’s Laboratories Ltd (India)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Beijing Four Rings Bio-Pharmaceutical Co.,Ltd. (China)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Kyowa Kirin Co., Ltd. (Japan)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global Erythropoiesis Stimulating Agents Sale, by Type, Application, Dosage, Drug Class and Region (value, volume and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Erythropoiesis Stimulating Agents (Value)
      • 7.2.1. Global Erythropoiesis Stimulating Agents by: Type (Value)
        • 7.2.1.1. Epoetin Alfa
        • 7.2.1.2. Epoetin Beta
        • 7.2.1.3. Epoetin Omega
        • 7.2.1.4. Epoetin Delta
        • 7.2.1.5. Darbepoetin Alfa
      • 7.2.2. Global Erythropoiesis Stimulating Agents by: Application (Value)
        • 7.2.2.1. Cancer
        • 7.2.2.2. Renal Disorders
        • 7.2.2.3. Anti-retroviral Treatment
        • 7.2.2.4. Neural Diseases
        • 7.2.2.5. Other
      • 7.2.3. Global Erythropoiesis Stimulating Agents by: Dosage (Value)
        • 7.2.3.1. 2000-4000 IU
        • 7.2.3.2. 6000-10000 IU
        • 7.2.3.3. Above 10000 IU
      • 7.2.4. Global Erythropoiesis Stimulating Agents by: Drug Class (Value)
        • 7.2.4.1. Biologics
        • 7.2.4.2. Biosimilars
      • 7.2.5. Global Erythropoiesis Stimulating Agents Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Erythropoiesis Stimulating Agents (Volume)
      • 7.3.1. Global Erythropoiesis Stimulating Agents by: Type (Volume)
        • 7.3.1.1. Epoetin Alfa
        • 7.3.1.2. Epoetin Beta
        • 7.3.1.3. Epoetin Omega
        • 7.3.1.4. Epoetin Delta
        • 7.3.1.5. Darbepoetin Alfa
      • 7.3.2. Global Erythropoiesis Stimulating Agents by: Application (Volume)
        • 7.3.2.1. Cancer
        • 7.3.2.2. Renal Disorders
        • 7.3.2.3. Anti-retroviral Treatment
        • 7.3.2.4. Neural Diseases
        • 7.3.2.5. Other
      • 7.3.3. Global Erythropoiesis Stimulating Agents by: Dosage (Volume)
        • 7.3.3.1. 2000-4000 IU
        • 7.3.3.2. 6000-10000 IU
        • 7.3.3.3. Above 10000 IU
      • 7.3.4. Global Erythropoiesis Stimulating Agents by: Drug Class (Volume)
        • 7.3.4.1. Biologics
        • 7.3.4.2. Biosimilars
      • 7.3.5. Global Erythropoiesis Stimulating Agents Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Erythropoiesis Stimulating Agents (Price)
      • 7.4.1. Global Erythropoiesis Stimulating Agents by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Erythropoiesis Stimulating Agents: by Type(USD Million)
  • Table 2. Erythropoiesis Stimulating Agents Epoetin Alfa , by Region USD Million (2014-2019)
  • Table 3. Erythropoiesis Stimulating Agents Epoetin Beta , by Region USD Million (2014-2019)
  • Table 4. Erythropoiesis Stimulating Agents Epoetin Omega , by Region USD Million (2014-2019)
  • Table 5. Erythropoiesis Stimulating Agents Epoetin Delta , by Region USD Million (2014-2019)
  • Table 6. Erythropoiesis Stimulating Agents Darbepoetin Alfa , by Region USD Million (2014-2019)
  • Table 7. Erythropoiesis Stimulating Agents: by Application(USD Million)
  • Table 8. Erythropoiesis Stimulating Agents Cancer , by Region USD Million (2014-2019)
  • Table 9. Erythropoiesis Stimulating Agents Renal Disorders , by Region USD Million (2014-2019)
  • Table 10. Erythropoiesis Stimulating Agents Anti-retroviral Treatment , by Region USD Million (2014-2019)
  • Table 11. Erythropoiesis Stimulating Agents Neural Diseases , by Region USD Million (2014-2019)
  • Table 12. Erythropoiesis Stimulating Agents Other , by Region USD Million (2014-2019)
  • Table 13. Erythropoiesis Stimulating Agents: by Dosage(USD Million)
  • Table 14. Erythropoiesis Stimulating Agents 2000-4000 IU , by Region USD Million (2014-2019)
  • Table 15. Erythropoiesis Stimulating Agents 6000-10000 IU , by Region USD Million (2014-2019)
  • Table 16. Erythropoiesis Stimulating Agents Above 10000 IU , by Region USD Million (2014-2019)
  • Table 17. Erythropoiesis Stimulating Agents: by Drug Class(USD Million)
  • Table 18. Erythropoiesis Stimulating Agents Biologics , by Region USD Million (2014-2019)
  • Table 19. Erythropoiesis Stimulating Agents Biosimilars , by Region USD Million (2014-2019)
  • Table 20. South America Erythropoiesis Stimulating Agents, by Country USD Million (2014-2019)
  • Table 21. South America Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 22. South America Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 23. South America Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 24. South America Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 25. Brazil Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 26. Brazil Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 27. Brazil Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 28. Brazil Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 29. Argentina Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 30. Argentina Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 31. Argentina Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 32. Argentina Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 33. Rest of South America Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 34. Rest of South America Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 35. Rest of South America Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 36. Rest of South America Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 37. Asia Pacific Erythropoiesis Stimulating Agents, by Country USD Million (2014-2019)
  • Table 38. Asia Pacific Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 39. Asia Pacific Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 40. Asia Pacific Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 41. Asia Pacific Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 42. China Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 43. China Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 44. China Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 45. China Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 46. Japan Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 47. Japan Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 48. Japan Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 49. Japan Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 50. India Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 51. India Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 52. India Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 53. India Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 54. South Korea Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 55. South Korea Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 56. South Korea Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 57. South Korea Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 58. Taiwan Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 59. Taiwan Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 60. Taiwan Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 61. Taiwan Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 62. Australia Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 63. Australia Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 64. Australia Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 65. Australia Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 66. Rest of Asia-Pacific Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 67. Rest of Asia-Pacific Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 68. Rest of Asia-Pacific Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 69. Rest of Asia-Pacific Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 70. Europe Erythropoiesis Stimulating Agents, by Country USD Million (2014-2019)
  • Table 71. Europe Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 72. Europe Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 73. Europe Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 74. Europe Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 75. Germany Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 76. Germany Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 77. Germany Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 78. Germany Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 79. France Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 80. France Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 81. France Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 82. France Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 83. Italy Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 84. Italy Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 85. Italy Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 86. Italy Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 87. United Kingdom Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 88. United Kingdom Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 89. United Kingdom Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 90. United Kingdom Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 91. Netherlands Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 92. Netherlands Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 93. Netherlands Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 94. Netherlands Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 95. Rest of Europe Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 96. Rest of Europe Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 97. Rest of Europe Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 98. Rest of Europe Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 99. MEA Erythropoiesis Stimulating Agents, by Country USD Million (2014-2019)
  • Table 100. MEA Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 101. MEA Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 102. MEA Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 103. MEA Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 104. Middle East Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 105. Middle East Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 106. Middle East Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 107. Middle East Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 108. Africa Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 109. Africa Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 110. Africa Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 111. Africa Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 112. North America Erythropoiesis Stimulating Agents, by Country USD Million (2014-2019)
  • Table 113. North America Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 114. North America Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 115. North America Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 116. North America Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 117. United States Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 118. United States Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 119. United States Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 120. United States Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 121. Canada Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 122. Canada Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 123. Canada Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 124. Canada Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 125. Mexico Erythropoiesis Stimulating Agents, by Type USD Million (2014-2019)
  • Table 126. Mexico Erythropoiesis Stimulating Agents, by Application USD Million (2014-2019)
  • Table 127. Mexico Erythropoiesis Stimulating Agents, by Dosage USD Million (2014-2019)
  • Table 128. Mexico Erythropoiesis Stimulating Agents, by Drug Class USD Million (2014-2019)
  • Table 129. Erythropoiesis Stimulating Agents Sales: by Type(K Tons)
  • Table 130. Erythropoiesis Stimulating Agents Sales Epoetin Alfa , by Region K Tons (2014-2019)
  • Table 131. Erythropoiesis Stimulating Agents Sales Epoetin Beta , by Region K Tons (2014-2019)
  • Table 132. Erythropoiesis Stimulating Agents Sales Epoetin Omega , by Region K Tons (2014-2019)
  • Table 133. Erythropoiesis Stimulating Agents Sales Epoetin Delta , by Region K Tons (2014-2019)
  • Table 134. Erythropoiesis Stimulating Agents Sales Darbepoetin Alfa , by Region K Tons (2014-2019)
  • Table 135. Erythropoiesis Stimulating Agents Sales: by Application(K Tons)
  • Table 136. Erythropoiesis Stimulating Agents Sales Cancer , by Region K Tons (2014-2019)
  • Table 137. Erythropoiesis Stimulating Agents Sales Renal Disorders , by Region K Tons (2014-2019)
  • Table 138. Erythropoiesis Stimulating Agents Sales Anti-retroviral Treatment , by Region K Tons (2014-2019)
  • Table 139. Erythropoiesis Stimulating Agents Sales Neural Diseases , by Region K Tons (2014-2019)
  • Table 140. Erythropoiesis Stimulating Agents Sales Other , by Region K Tons (2014-2019)
  • Table 141. Erythropoiesis Stimulating Agents Sales: by Dosage(K Tons)
  • Table 142. Erythropoiesis Stimulating Agents Sales 2000-4000 IU , by Region K Tons (2014-2019)
  • Table 143. Erythropoiesis Stimulating Agents Sales 6000-10000 IU , by Region K Tons (2014-2019)
  • Table 144. Erythropoiesis Stimulating Agents Sales Above 10000 IU , by Region K Tons (2014-2019)
  • Table 145. Erythropoiesis Stimulating Agents Sales: by Drug Class(K Tons)
  • Table 146. Erythropoiesis Stimulating Agents Sales Biologics , by Region K Tons (2014-2019)
  • Table 147. Erythropoiesis Stimulating Agents Sales Biosimilars , by Region K Tons (2014-2019)
  • Table 148. South America Erythropoiesis Stimulating Agents Sales, by Country K Tons (2014-2019)
  • Table 149. South America Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 150. South America Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 151. South America Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 152. South America Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 153. Brazil Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 154. Brazil Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 155. Brazil Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 156. Brazil Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 157. Argentina Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 158. Argentina Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 159. Argentina Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 160. Argentina Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 161. Rest of South America Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 162. Rest of South America Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 163. Rest of South America Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 164. Rest of South America Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 165. Asia Pacific Erythropoiesis Stimulating Agents Sales, by Country K Tons (2014-2019)
  • Table 166. Asia Pacific Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 167. Asia Pacific Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 168. Asia Pacific Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 169. Asia Pacific Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 170. China Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 171. China Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 172. China Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 173. China Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 174. Japan Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 175. Japan Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 176. Japan Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 177. Japan Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 178. India Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 179. India Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 180. India Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 181. India Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 182. South Korea Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 183. South Korea Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 184. South Korea Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 185. South Korea Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 186. Taiwan Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 187. Taiwan Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 188. Taiwan Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 189. Taiwan Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 190. Australia Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 191. Australia Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 192. Australia Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 193. Australia Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 194. Rest of Asia-Pacific Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 195. Rest of Asia-Pacific Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 196. Rest of Asia-Pacific Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 197. Rest of Asia-Pacific Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 198. Europe Erythropoiesis Stimulating Agents Sales, by Country K Tons (2014-2019)
  • Table 199. Europe Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 200. Europe Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 201. Europe Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 202. Europe Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 203. Germany Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 204. Germany Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 205. Germany Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 206. Germany Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 207. France Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 208. France Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 209. France Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 210. France Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 211. Italy Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 212. Italy Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 213. Italy Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 214. Italy Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 215. United Kingdom Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 216. United Kingdom Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 217. United Kingdom Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 218. United Kingdom Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 219. Netherlands Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 220. Netherlands Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 221. Netherlands Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 222. Netherlands Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 223. Rest of Europe Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 224. Rest of Europe Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 225. Rest of Europe Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 226. Rest of Europe Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 227. MEA Erythropoiesis Stimulating Agents Sales, by Country K Tons (2014-2019)
  • Table 228. MEA Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 229. MEA Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 230. MEA Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 231. MEA Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 232. Middle East Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 233. Middle East Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 234. Middle East Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 235. Middle East Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 236. Africa Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 237. Africa Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 238. Africa Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 239. Africa Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 240. North America Erythropoiesis Stimulating Agents Sales, by Country K Tons (2014-2019)
  • Table 241. North America Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 242. North America Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 243. North America Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 244. North America Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 245. United States Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 246. United States Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 247. United States Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 248. United States Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 249. Canada Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 250. Canada Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 251. Canada Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 252. Canada Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 253. Mexico Erythropoiesis Stimulating Agents Sales, by Type K Tons (2014-2019)
  • Table 254. Mexico Erythropoiesis Stimulating Agents Sales, by Application K Tons (2014-2019)
  • Table 255. Mexico Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2014-2019)
  • Table 256. Mexico Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2014-2019)
  • Table 257. Erythropoiesis Stimulating Agents: by Type(USD/Units)
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Company Basic Information, Sales Area and Its Competitors
  • Table 271. Company Basic Information, Sales Area and Its Competitors
  • Table 272. Company Basic Information, Sales Area and Its Competitors
  • Table 273. Erythropoiesis Stimulating Agents: by Type(USD Million)
  • Table 274. Erythropoiesis Stimulating Agents Epoetin Alfa , by Region USD Million (2020-2025)
  • Table 275. Erythropoiesis Stimulating Agents Epoetin Beta , by Region USD Million (2020-2025)
  • Table 276. Erythropoiesis Stimulating Agents Epoetin Omega , by Region USD Million (2020-2025)
  • Table 277. Erythropoiesis Stimulating Agents Epoetin Delta , by Region USD Million (2020-2025)
  • Table 278. Erythropoiesis Stimulating Agents Darbepoetin Alfa , by Region USD Million (2020-2025)
  • Table 279. Erythropoiesis Stimulating Agents: by Application(USD Million)
  • Table 280. Erythropoiesis Stimulating Agents Cancer , by Region USD Million (2020-2025)
  • Table 281. Erythropoiesis Stimulating Agents Renal Disorders , by Region USD Million (2020-2025)
  • Table 282. Erythropoiesis Stimulating Agents Anti-retroviral Treatment , by Region USD Million (2020-2025)
  • Table 283. Erythropoiesis Stimulating Agents Neural Diseases , by Region USD Million (2020-2025)
  • Table 284. Erythropoiesis Stimulating Agents Other , by Region USD Million (2020-2025)
  • Table 285. Erythropoiesis Stimulating Agents: by Dosage(USD Million)
  • Table 286. Erythropoiesis Stimulating Agents 2000-4000 IU , by Region USD Million (2020-2025)
  • Table 287. Erythropoiesis Stimulating Agents 6000-10000 IU , by Region USD Million (2020-2025)
  • Table 288. Erythropoiesis Stimulating Agents Above 10000 IU , by Region USD Million (2020-2025)
  • Table 289. Erythropoiesis Stimulating Agents: by Drug Class(USD Million)
  • Table 290. Erythropoiesis Stimulating Agents Biologics , by Region USD Million (2020-2025)
  • Table 291. Erythropoiesis Stimulating Agents Biosimilars , by Region USD Million (2020-2025)
  • Table 292. South America Erythropoiesis Stimulating Agents, by Country USD Million (2020-2025)
  • Table 293. South America Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 294. South America Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 295. South America Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 296. South America Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 297. Brazil Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 298. Brazil Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 299. Brazil Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 300. Brazil Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 301. Argentina Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 302. Argentina Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 303. Argentina Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 304. Argentina Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 305. Rest of South America Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 306. Rest of South America Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 307. Rest of South America Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 308. Rest of South America Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 309. Asia Pacific Erythropoiesis Stimulating Agents, by Country USD Million (2020-2025)
  • Table 310. Asia Pacific Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 311. Asia Pacific Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 312. Asia Pacific Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 313. Asia Pacific Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 314. China Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 315. China Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 316. China Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 317. China Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 318. Japan Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 319. Japan Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 320. Japan Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 321. Japan Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 322. India Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 323. India Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 324. India Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 325. India Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 326. South Korea Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 327. South Korea Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 328. South Korea Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 329. South Korea Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 330. Taiwan Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 331. Taiwan Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 332. Taiwan Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 333. Taiwan Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 334. Australia Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 335. Australia Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 336. Australia Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 337. Australia Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 338. Rest of Asia-Pacific Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 339. Rest of Asia-Pacific Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 340. Rest of Asia-Pacific Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 341. Rest of Asia-Pacific Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 342. Europe Erythropoiesis Stimulating Agents, by Country USD Million (2020-2025)
  • Table 343. Europe Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 344. Europe Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 345. Europe Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 346. Europe Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 347. Germany Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 348. Germany Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 349. Germany Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 350. Germany Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 351. France Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 352. France Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 353. France Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 354. France Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 355. Italy Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 356. Italy Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 357. Italy Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 358. Italy Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 359. United Kingdom Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 360. United Kingdom Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 361. United Kingdom Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 362. United Kingdom Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 363. Netherlands Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 364. Netherlands Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 365. Netherlands Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 366. Netherlands Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 367. Rest of Europe Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 368. Rest of Europe Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 369. Rest of Europe Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 370. Rest of Europe Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 371. MEA Erythropoiesis Stimulating Agents, by Country USD Million (2020-2025)
  • Table 372. MEA Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 373. MEA Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 374. MEA Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 375. MEA Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 376. Middle East Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 377. Middle East Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 378. Middle East Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 379. Middle East Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 380. Africa Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 381. Africa Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 382. Africa Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 383. Africa Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 384. North America Erythropoiesis Stimulating Agents, by Country USD Million (2020-2025)
  • Table 385. North America Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 386. North America Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 387. North America Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 388. North America Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 389. United States Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 390. United States Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 391. United States Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 392. United States Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 393. Canada Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 394. Canada Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 395. Canada Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 396. Canada Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 397. Mexico Erythropoiesis Stimulating Agents, by Type USD Million (2020-2025)
  • Table 398. Mexico Erythropoiesis Stimulating Agents, by Application USD Million (2020-2025)
  • Table 399. Mexico Erythropoiesis Stimulating Agents, by Dosage USD Million (2020-2025)
  • Table 400. Mexico Erythropoiesis Stimulating Agents, by Drug Class USD Million (2020-2025)
  • Table 401. Erythropoiesis Stimulating Agents Sales: by Type(K Tons)
  • Table 402. Erythropoiesis Stimulating Agents Sales Epoetin Alfa , by Region K Tons (2020-2025)
  • Table 403. Erythropoiesis Stimulating Agents Sales Epoetin Beta , by Region K Tons (2020-2025)
  • Table 404. Erythropoiesis Stimulating Agents Sales Epoetin Omega , by Region K Tons (2020-2025)
  • Table 405. Erythropoiesis Stimulating Agents Sales Epoetin Delta , by Region K Tons (2020-2025)
  • Table 406. Erythropoiesis Stimulating Agents Sales Darbepoetin Alfa , by Region K Tons (2020-2025)
  • Table 407. Erythropoiesis Stimulating Agents Sales: by Application(K Tons)
  • Table 408. Erythropoiesis Stimulating Agents Sales Cancer , by Region K Tons (2020-2025)
  • Table 409. Erythropoiesis Stimulating Agents Sales Renal Disorders , by Region K Tons (2020-2025)
  • Table 410. Erythropoiesis Stimulating Agents Sales Anti-retroviral Treatment , by Region K Tons (2020-2025)
  • Table 411. Erythropoiesis Stimulating Agents Sales Neural Diseases , by Region K Tons (2020-2025)
  • Table 412. Erythropoiesis Stimulating Agents Sales Other , by Region K Tons (2020-2025)
  • Table 413. Erythropoiesis Stimulating Agents Sales: by Dosage(K Tons)
  • Table 414. Erythropoiesis Stimulating Agents Sales 2000-4000 IU , by Region K Tons (2020-2025)
  • Table 415. Erythropoiesis Stimulating Agents Sales 6000-10000 IU , by Region K Tons (2020-2025)
  • Table 416. Erythropoiesis Stimulating Agents Sales Above 10000 IU , by Region K Tons (2020-2025)
  • Table 417. Erythropoiesis Stimulating Agents Sales: by Drug Class(K Tons)
  • Table 418. Erythropoiesis Stimulating Agents Sales Biologics , by Region K Tons (2020-2025)
  • Table 419. Erythropoiesis Stimulating Agents Sales Biosimilars , by Region K Tons (2020-2025)
  • Table 420. South America Erythropoiesis Stimulating Agents Sales, by Country K Tons (2020-2025)
  • Table 421. South America Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 422. South America Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 423. South America Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 424. South America Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 425. Brazil Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 426. Brazil Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 427. Brazil Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 428. Brazil Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 429. Argentina Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 430. Argentina Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 431. Argentina Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 432. Argentina Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 433. Rest of South America Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 434. Rest of South America Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 435. Rest of South America Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 436. Rest of South America Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 437. Asia Pacific Erythropoiesis Stimulating Agents Sales, by Country K Tons (2020-2025)
  • Table 438. Asia Pacific Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 439. Asia Pacific Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 440. Asia Pacific Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 441. Asia Pacific Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 442. China Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 443. China Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 444. China Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 445. China Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 446. Japan Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 447. Japan Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 448. Japan Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 449. Japan Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 450. India Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 451. India Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 452. India Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 453. India Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 454. South Korea Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 455. South Korea Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 456. South Korea Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 457. South Korea Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 458. Taiwan Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 459. Taiwan Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 460. Taiwan Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 461. Taiwan Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 462. Australia Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 463. Australia Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 464. Australia Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 465. Australia Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 466. Rest of Asia-Pacific Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 467. Rest of Asia-Pacific Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 468. Rest of Asia-Pacific Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 469. Rest of Asia-Pacific Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 470. Europe Erythropoiesis Stimulating Agents Sales, by Country K Tons (2020-2025)
  • Table 471. Europe Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 472. Europe Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 473. Europe Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 474. Europe Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 475. Germany Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 476. Germany Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 477. Germany Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 478. Germany Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 479. France Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 480. France Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 481. France Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 482. France Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 483. Italy Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 484. Italy Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 485. Italy Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 486. Italy Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 487. United Kingdom Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 488. United Kingdom Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 489. United Kingdom Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 490. United Kingdom Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 491. Netherlands Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 492. Netherlands Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 493. Netherlands Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 494. Netherlands Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 495. Rest of Europe Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 496. Rest of Europe Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 497. Rest of Europe Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 498. Rest of Europe Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 499. MEA Erythropoiesis Stimulating Agents Sales, by Country K Tons (2020-2025)
  • Table 500. MEA Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 501. MEA Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 502. MEA Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 503. MEA Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 504. Middle East Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 505. Middle East Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 506. Middle East Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 507. Middle East Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 508. Africa Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 509. Africa Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 510. Africa Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 511. Africa Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 512. North America Erythropoiesis Stimulating Agents Sales, by Country K Tons (2020-2025)
  • Table 513. North America Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 514. North America Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 515. North America Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 516. North America Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 517. United States Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 518. United States Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 519. United States Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 520. United States Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 521. Canada Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 522. Canada Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 523. Canada Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 524. Canada Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 525. Mexico Erythropoiesis Stimulating Agents Sales, by Type K Tons (2020-2025)
  • Table 526. Mexico Erythropoiesis Stimulating Agents Sales, by Application K Tons (2020-2025)
  • Table 527. Mexico Erythropoiesis Stimulating Agents Sales, by Dosage K Tons (2020-2025)
  • Table 528. Mexico Erythropoiesis Stimulating Agents Sales, by Drug Class K Tons (2020-2025)
  • Table 529. Erythropoiesis Stimulating Agents: by Type(USD/Units)
  • Table 530. Research Programs/Design for This Report
  • Table 531. Key Data Information from Secondary Sources
  • Table 532. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Erythropoiesis Stimulating Agents: by Type USD Million (2014-2019)
  • Figure 5. Global Erythropoiesis Stimulating Agents: by Application USD Million (2014-2019)
  • Figure 6. Global Erythropoiesis Stimulating Agents: by Dosage USD Million (2014-2019)
  • Figure 7. Global Erythropoiesis Stimulating Agents: by Drug Class USD Million (2014-2019)
  • Figure 8. South America Erythropoiesis Stimulating Agents Share (%), by Country
  • Figure 9. Asia Pacific Erythropoiesis Stimulating Agents Share (%), by Country
  • Figure 10. Europe Erythropoiesis Stimulating Agents Share (%), by Country
  • Figure 11. MEA Erythropoiesis Stimulating Agents Share (%), by Country
  • Figure 12. North America Erythropoiesis Stimulating Agents Share (%), by Country
  • Figure 13. Global Erythropoiesis Stimulating Agents: by Type K Tons (2014-2019)
  • Figure 14. Global Erythropoiesis Stimulating Agents: by Application K Tons (2014-2019)
  • Figure 15. Global Erythropoiesis Stimulating Agents: by Dosage K Tons (2014-2019)
  • Figure 16. Global Erythropoiesis Stimulating Agents: by Drug Class K Tons (2014-2019)
  • Figure 17. South America Erythropoiesis Stimulating Agents Share (%), by Country
  • Figure 18. Asia Pacific Erythropoiesis Stimulating Agents Share (%), by Country
  • Figure 19. Europe Erythropoiesis Stimulating Agents Share (%), by Country
  • Figure 20. MEA Erythropoiesis Stimulating Agents Share (%), by Country
  • Figure 21. North America Erythropoiesis Stimulating Agents Share (%), by Country
  • Figure 22. Global Erythropoiesis Stimulating Agents: by Type USD/Units (2014-2019)
  • Figure 23. Global Erythropoiesis Stimulating Agents share by Players 2019 (%)
  • Figure 24. Global Erythropoiesis Stimulating Agents share by Players (Top 3) 2019(%)
  • Figure 25. Global Erythropoiesis Stimulating Agents share by Players (Top 5) 2019(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Amgen Inc. (United States) Revenue: by Geography 2019
  • Figure 29. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 30. Thermo Fisher Scientific (United States) Revenue: by Geography 2019
  • Figure 31. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 32. Johnson and Johnson (United States) Revenue: by Geography 2019
  • Figure 33. F. Hoffmann La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. F. Hoffmann La Roche (Switzerland) Revenue: by Geography 2019
  • Figure 35. Pfizer, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 36. Pfizer, Inc (United States) Revenue: by Geography 2019
  • Figure 37. Celltrion, Inc (South Korea) Revenue, Net Income and Gross profit
  • Figure 38. Celltrion, Inc (South Korea) Revenue: by Geography 2019
  • Figure 39. BioSidus (Argentina) Revenue, Net Income and Gross profit
  • Figure 40. BioSidus (Argentina) Revenue: by Geography 2019
  • Figure 41. Intas Pharmaceuticals Ltd (India) Revenue, Net Income and Gross profit
  • Figure 42. Intas Pharmaceuticals Ltd (India) Revenue: by Geography 2019
  • Figure 43. Teva Pharmaceutical Industries Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 44. Teva Pharmaceutical Industries Ltd (Israel) Revenue: by Geography 2019
  • Figure 45. Ranbaxy Laboratories Ltd (India) Revenue, Net Income and Gross profit
  • Figure 46. Ranbaxy Laboratories Ltd (India) Revenue: by Geography 2019
  • Figure 47. LG Life Sciences Ltd. (South Korea) Revenue, Net Income and Gross profit
  • Figure 48. LG Life Sciences Ltd. (South Korea) Revenue: by Geography 2019
  • Figure 49. VHB Life Sciences Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 50. VHB Life Sciences Ltd. (India) Revenue: by Geography 2019
  • Figure 51. Dr. Reddy’s Laboratories Ltd (India) Revenue, Net Income and Gross profit
  • Figure 52. Dr. Reddy’s Laboratories Ltd (India) Revenue: by Geography 2019
  • Figure 53. Beijing Four Rings Bio-Pharmaceutical Co.,Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 54. Beijing Four Rings Bio-Pharmaceutical Co.,Ltd. (China) Revenue: by Geography 2019
  • Figure 55. Kyowa Kirin Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 56. Kyowa Kirin Co., Ltd. (Japan) Revenue: by Geography 2019
  • Figure 57. Global Erythropoiesis Stimulating Agents: by Type USD Million (2020-2025)
  • Figure 58. Global Erythropoiesis Stimulating Agents: by Application USD Million (2020-2025)
  • Figure 59. Global Erythropoiesis Stimulating Agents: by Dosage USD Million (2020-2025)
  • Figure 60. Global Erythropoiesis Stimulating Agents: by Drug Class USD Million (2020-2025)
  • Figure 61. South America Erythropoiesis Stimulating Agents Share (%), by Country
  • Figure 62. Asia Pacific Erythropoiesis Stimulating Agents Share (%), by Country
  • Figure 63. Europe Erythropoiesis Stimulating Agents Share (%), by Country
  • Figure 64. MEA Erythropoiesis Stimulating Agents Share (%), by Country
  • Figure 65. North America Erythropoiesis Stimulating Agents Share (%), by Country
  • Figure 66. Global Erythropoiesis Stimulating Agents: by Type K Tons (2020-2025)
  • Figure 67. Global Erythropoiesis Stimulating Agents: by Application K Tons (2020-2025)
  • Figure 68. Global Erythropoiesis Stimulating Agents: by Dosage K Tons (2020-2025)
  • Figure 69. Global Erythropoiesis Stimulating Agents: by Drug Class K Tons (2020-2025)
  • Figure 70. South America Erythropoiesis Stimulating Agents Share (%), by Country
  • Figure 71. Asia Pacific Erythropoiesis Stimulating Agents Share (%), by Country
  • Figure 72. Europe Erythropoiesis Stimulating Agents Share (%), by Country
  • Figure 73. MEA Erythropoiesis Stimulating Agents Share (%), by Country
  • Figure 74. North America Erythropoiesis Stimulating Agents Share (%), by Country
  • Figure 75. Global Erythropoiesis Stimulating Agents: by Type USD/Units (2020-2025)
Some of the key companies/manufacturers profiled in the report
  • Amgen Inc. (United States)
  • Thermo Fisher Scientific (United States)
  • Johnson and Johnson (United States)
  • F. Hoffmann La Roche (Switzerland)
  • Pfizer, Inc (United States)
  • Celltrion, Inc (South Korea)
  • BioSidus (Argentina)
  • Intas Pharmaceuticals Ltd (India)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Ranbaxy Laboratories Ltd (India)
  • LG Life Sciences Ltd. (South Korea)
  • VHB Life Sciences Ltd. (India)
  • Dr. Reddy’s Laboratories Ltd (India)
  • Beijing Four Rings Bio-Pharmaceutical Co.,Ltd. (China)
  • Kyowa Kirin Co., Ltd. (Japan)
Additional players considered in the study are as follows:
Zuventus Health Care (India) , Serum Institute of India (India) , Biocon Limited (India) , Shandong Kexing Bioproducts Co. Ltd (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation